Kornimate/medical-research-clean huggingface dataset:
validation of the respirio flu test for the rapid identification of influenza a/b

Conditions: Influenza

Summary: this is a open label, prospective, pair comparison, randomised, multi-centre trial. the primary aim of this study to is to clinically validate the sensitivity and specificity of the respirio flu test (rft) in detecting influenza a as compared with (a) the best available rapid influenza a test in the market quidel quickvue (qqv) and (b) the gold standard for identifying influenza a infection polymerase chain reaction (pcr). the secondary aim is to clinically validate the sensitivity and specificity of the respirio flu test (rft) in detecting influenza b as compared to qqv and pcr.


Eligibility criteria:
inclusion criteria: 1. male and female subjects aged between 7 and 80 years (inclusive); 2. fever \> 37.5 or a self-reported history of fever or feeling feverish (includes fever controlled by medication) in the absence of documented fever; 3. cough or sore throat; 4. rhinorrhea or nasal congestion; 5. ≤ 5 days from onset of clinical influenza - like illness (ili) symptoms; 6. subject (or parent/guardian) capable and willing to give informed consent; 7. subject provides written assent according to his/her age, if applicable. exclusion criteria: 1. recent craniofacial abnormality or injury (last 3 months); 2. nasal or sinus surgery, including surgery to correct deviation of the nasal septum, within the previous 6 months; 3. craniofacial abnormality, such as severe deviation of the nasal septum; 4. onset of clinical influenza - like illness (ili) symptoms \> 5 days; 5. know history of allergic reaction to plastics or adhesives; 6. subject (or parent/guardian) unwilling or unable to give informed consent.

Keywords: influenza human orthomyxoviridae infections rna virus infections virus diseases respiratory tract infections respiratory tract diseases
a study of jnj-77242113 in participants with moderate-to-severe plaque psoriasis

Conditions: Plaque Psoriasis

Summary: th purpose of the study is to evaluate the dose response of jnj-77242113 in efficacy at week 16 in participants with moderate-to-severe plaque psoriasis.

the populations of people living with moderate to severe psoriasis is approximately 3.5 billion which are mostly managed with topical and conventional therapies. jnj-77242113, investigational drug, targets the immune responses in the body and skin which impacts diseases, such as psoriasis and psoriatic arthritis (psa) and this study evaluates jnj-77242113 as options of advanced therapies in moderate to severe plaque psoriasis. the total duration of this study is up to 24 weeks which includes a screening period of less than or equal to (\<=) 4 weeks, a 16-week treatment period, and a 4-week safety follow-up period. safety will be assessed by adverse events (aes), clinical safety laboratory assessments, electrocardiograms (ecgs), vital signs and physical examinations.

Eligibility criteria:
inclusion criteria: * participant has a diagnosis of plaque psoriasis, with or without psoriatic arthritis (psa), for at least 6 months prior to the first administration of study intervention * participant be a candidate for phototherapy or systemic treatment for plaque psoriasis * participant has a total body surface area (bsa) greater than or equal to (\>=)10 percent (%) at screening and baseline * participant has a total psoriasis area and severity index (pasi) \>=12 at screening and baseline * participant has a total investigator global assessment (iga) \>=3 at screening and baseline exclusion criteria: * participant has a nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular) * participant has current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium) * participant have previously received any other therapeutic agent directly targeted to interleukin 23 receptor (il-23r) (including but not limited to guselkumab, tildrakizumab, or risankizumab) * participant has received any therapeutic agent directly targeted to interleukin 17 receptor (il-17) or interleukin 12/23 receptor (il-12/23) (including but not limited to secukinumab, ixekizumab, brodalumab, or ustekinumab) or has received anti-tumor necrosis factor \[tnf\]-alpha biologic therapy (including, but not limited to adalimumab) within 12 weeks or 5 half-lives, whichever is longer, of the first administration of study intervention * participant has received agents that deplete b cells (including, but not limited to, rituximab, or alemtuzumab) within 26 weeks of the first administration of study intervention
recovery of soccer players after anterior cruciate ligament reconstruction.

Conditions: Knee Injuries and Disorders

Summary: the purpose of this crt study is to compare clinical and functional outcomes of three graft types ( quadriceps tendon with bone versus hamstring tendon versus quadriceps tendon without bone) for reconstration of anterior cruciate ligament among football players.

in the previous studies patellar tendon and hamstring tendon were the most investigated graft types. while quadriceps tendon has been investigated a fewer times. and to our knowledge there is no control study that compare quadriceps tendon-patellar bone autograft with quadriceps autograft and hamstring autograft as control randomized study. all of the patients will be examined before of the surgery and 3, 6, 12, 24 months after the surgery to compare the outcome of differnt graft types. while a secand aim of this study is to examen the effect of rehabilitation protocol on the short and long term within all of the clinical and the functional outcomes. the rehabilitation protocol will contain one phase before the surgery and four phases after the surgery.the goal of the first phase will be pain and inflammation control, increase rom and muscle strength will be during the second and the third phases.in the last phase all of the players have to achieve maximum muscle strength and neuromuscular control.

Eligibility criteria:
inclusion criteria: * patients with acl injury susceptible to receive a surgical reconstruction. * autograft with hamstring tendon ,quadriceps tendon or quadriceps tendon with patellar bone. * soccer player for more than 3 years. * between 16 and 40 years old. exclusion criteria: * patient with previous joint injury. * patient with previous surgery on the affected knee. * patient with previous musculoskeletal injury (4 weeks) * patient with untreated chronic injury.

Keywords: aclr quadricepses tendon graft hamstring tendon graft
treca - treatment of colorectal adenomas and early colorectal cancer in region västra götaland

Conditions: Rectal Neoplasms

Summary: all early colorectal cancers (t1-t2) treated in the region västra götaland from 2007-2020 will be evaluated. to establish the extent to which early colorectal cancers have been treated with local excision? how have treatment strategies changed over time? the study will provide information on where these patients have been treated in the region västra götaland. during the study period, esd was introduced as a treatment modality, and it will investigated how this may have influenced treatment strategies for complex adenomas. clinical outcome measures will include recurrence rates and re-intervention rates for the respective treatments. possible areas of improvement will be identified and determine if evidence based and best practice guidelines are met with the current treatment strategies in region västra götaland.


Eligibility criteria:
inclusion criteria: * rectal cancer resected by local resection exclusion criteria: * all other types of resection or treatment for rectal cancer
study of key electro-acupuncture technique on migraine

Conditions: Migraine

Summary: a random controlled trail to evaluate the efficacy of migraine standard electroacupuncture formula, and to analysis the regulation of the intensity-effects and to observe the peripheral no, cgrp and nf-кb expression level of migraine patients after electroacupuncture treatment.

acupuncture group(group a): treated by acupuncture for 20 days, 1 time per day control group(group b): treated by flunarizinehydrochloride for 20 days, 1 table per day.

Eligibility criteria:
inclusion criteria: * met the diagnostic criteria for migraine; suffering from migraine attacks; migraine attacks for more than 5 days per month, and lasts for 3 months; voluntarily join this study with informed consents. exclusion criteria: * other systemic, neurological and psychiatric disorders; headache caused by other diseases; not treatment compliance during the study.

Keywords: electroacupuncture therapy migraine acupuncture therapy
preparing heart and mind™: a patient engagement pathway for parents and their caregiving partners after a major fetal anomaly diagnosis

Conditions: Parent Mental Health

Summary: the purpose of this study is to test and evaluate the preparing heart and mind™ (phm™) patient engagement pathway as a nurse-guided intervention to lower psychological distress and enhance caregiving competencies among mothers/birthing persons and their caregiving partners after a major fetal anomaly diagnosis.


Eligibility criteria:
inclusion criteria: * a study participant can include a pregnant person past 20 weeks of pregnancy (this includes a vulnerable population) * willing and able to comply with study procedures. * participants must be ≥ 18 years old. * participants must be able to read, write and speak english. * participants must have access, and ability to use a smartphone, tablet, or computer in a private location. * the pregnant woman/person and her caregiving partner are planning for infant delivery and care. * the fetal diagnosis of the major anomaly affects the heart (i.e., cchd). see definition of cchd included earlier in the protocol. other anomalies could be present and potentially impair other organs. * the infant's anomaly will likely require surgical and/or medical intervention within the first year of life. * the fetus/infant is expected to live with surgical and/or medical intervention (this includes a vulnerable population). * there may be genetic and/or chromosomal conditions in addition to the heart/structural anomalies exclusion criteria: * pregnancy termination * the fetal anomaly diagnosis is highly likely to result in fetal or infant demise shortly after birth. * adults lacking the capacity to consent * adults who do not have access to a smart phone, tablet, or device. * caregiving partner cannot enroll if mother is not enrolled

Keywords: parent fetal anomaly prenatal diagnosis infant heart disease ehealth intervention
plasma concentration of biological markers in placental abruption

Conditions: Abruptio Placentae

Summary: this will be a prospective study conducted on women with a suspected/confirmed diagnosis of placental abruption. maternal blood samples will be taken at various points during the peripartum period. a healthy group of women admitted for delivery will act as a matched control and will have their blood sampled at similar time points. the primary outcome variables will include the total number of micro-particles, the number of micro-particles from each cell line (platelet, placental, endothelial etc.), and protein markers (specifically; placental growth factor (plgf), soluble fms-like tyrosine kinase-1 (sflt-1), vascular endothelial growth factor (vegf), soluble endoglin (seng)). secondary outcomes if will examine the correlation between placental micro-particles, biomarkers, and extent of placental abruption.

the purpose of this study is to determine how well maternal serum biomarkers and placental micro-particles (mp) correlate with pa. the sensitivity and specificity of these proteins will be analyzed to further increase our understanding of the pathological mechanisms involved in pa. the knowledge gained from this study has the potential to develop a diagnostic test for pa with the ability to improve outcomes for mother and baby through earlier diagnosis and targeted therapy.

Eligibility criteria:
inclusion criteria: * age 18 - to 45-years old, inclusive * suspected or confirmed pa or phenotypically matched controls * all modes of delivery * gestational age greater than 28 weeks * singleton pregnancy exclusion criteria: * intrauterine fetal demise, * severe fetal anomalies (infant not expected to survive) * inability to communicate in english
a performance evaluation study of arquer's mcm5 elisa test (adxbladder) to aid in the monitoring of recurrence in non-muscle invasive bladder cancer

Conditions: Bladder Cancer

Summary: the objective of this prospective, multi-centre study is to evaluate the performance of adxbladder, a urine mcm5 elisa test, as an aid in the detection of bladder cancer recurrence. patients undergoing cystoscopic surveillance in non-muscle invasive bladder cancer (nmibc) follow-up will be recruited and asked to provide a urine sample to be tested with adxbladder. to assess the diagnostic accuracy of the test, the mcm5 results will be compared with the gold standard cystoscopy and pathology of resected tissue.


Eligibility criteria:
inclusion criteria: * patients who have been diagnosed with nmibc in the previous 2 years, and are attending the urology clinic for standard of care/routine monitoring cystoscopy * patients 22 years of age or older * patients who, in the opinion of the investigator, are suitable for standard urological investigations as part of normal clinical practice * patients who are, in the opinion of the investigator, able to understand the purpose of the study and provide a full void urine specimen * patients who are able to give voluntary, written informed consent to participate in this study exclusion criteria: * patients with known active (symptomatic) calculi within the urino-genitary system * patients who provide less than 10ml of full void urine * patients undergoing active treatment for interstitial cystitis * patients currently undergoing systemic chemotherapy or systemic immunotherapy or radiotherapy. intravesical chemotherapy or immunotherapy (bcg) is allowed * patients who have previously been diagnosed with renal cancer, prostate cancer, muscle invasive bladder cancer, an upper tract tumour, or cis in the prostatic urethra * patients who have had urological instrumentation to the urinary tract within 14 days prior to the test * male patients undergoing active treatment for prostatitis

Keywords: bladder cancer non-muscle invasive bladder cancer mcm5 biomarker urinary biomarker follow-up surveillance
baseline performance and fitting parameters for sonova products

Conditions: Hearing Loss; Ear Diseases; Hearing Disorders; Otolaryngological Disease

Summary: the purpose of this study is to assess the effectiveness and optimization of various fda approved products.

this study uses a prospective within-subjects repeated-measures design in which each subject serves as her/his own control. the purpose of this study is to assess the effectiveness and optimization of various fda approved hardware, signal preprocessing and processing software, fitting characteristics, and service delivery methods, such as remote support and/or tele-audiology on an expanded subject demographic. the insights gained from this study will be used to optimize listening configuration recommendations, refine audiological practice, and inform future innovations.

Eligibility criteria:
inclusion criteria: * ability to provide informed consent/assent * adults (age +18 years) and children (8-17 years) can be enrolled in this study * if child is aged 8-17 years, an assent will be completed, and the subject must be accompanied by a parent or legal guardian for all study activities * have the functional capability to operate the controls for the device and to comply with all directions during the study as determined by the investigator conducting the consent/baseline visit * english language proficiency as determined by the investigator exclusion criteria: • have any significant medical condition that, in the opinion of any of the investigators, is likely to interfere with study procedures or likely to confound evaluation of study endpoints
treating primary sclerosing cholangitis and biliary atresia with vancomycin

Conditions: Primary Sclerosing Cholangitis; Biliary Atresia

Summary: the purpose of this study is twofold. first, is to determine whether vancomycin is effective in the early treatment of biliary atresia (ba) and primary sclerosing cholangitis (psc), and if so, by what mechanism. secondly, to characterize human intestinal microbial communities and their interactions with the host.

investigators hope to learn to characterize human intestinal microbial communities (microbiome: the collection or collectivity of microorganisms) using molecular methods, examine the mechanisms of interaction between host and microbiome using genomic approaches, and determine how the microbiome both preserves local health and promotes pathology. investigation will focus on primary sclerosing cholangitis, biliary atresia, as well as states of health. the composition of the associated microbiome will be assessed based on ribosomal dna and rna sequences, and attention will be given to richness (diversity), evenness (relative abundance), and variation with respect to time, person, and anatomic niche. host response at the adjacent mucosal surface will be assessed based on genome-wide gene expression patterns. in addition, changes in the metabolites of the blood will be analyzed. to see if the antibiotic vancomycin, when used for the early treatment of biliary atresia (ba) and primary sclerosing cholangitis (psc) is effective treatment for these diseases. investigators hope to learn what effect vancomycin has on the bacteria that are present in stool, body fluid or intestinal tissue on someone who has ba and psc and if so by what mechanism.

Eligibility criteria:
inclusion criteria: * persons who have primary sclerosing cholangitis, biliary atresia, a chronic intestinal disorder or who are undergoing upper or lower endoscopy. * persons who have primary sclerosing cholangitis or biliary atresia who are good candidates for vancomycin therapy. exclusion criteria: * patients that have taken antibiotics and/or immunomodulators within the last 3 months will be excluded as this will alter the original bacterial flora. * females who are pregnant may not participate.
fluid responsiveness tests in critically ill patients during admission to the intensive care unit

Conditions: Shock Circulatory; Heart Failure; Hypovolemia

Summary: the goal of this observational study is to investigate the prevalence of conditions allowing the performance fluid responsiveness tests in critically ill patients during admission to the intensive care unit.

patients admitted to the intensive care unit are very often hemodynamically unstable. in these cases fluid responsiveness tests should be performed to assess whether the patient would benefit from the fluid administration. however, fluid responsiveness tests have many limitations including lack of spontaneous breathing, necessity of invasive mechanical ventilation with tidal volume of \> 8 ml/kg ideal body weight, regular hearth rhythm, and lack of abdominal hypertension. in the study, the investigators evaluated the prevalence of conditions enabling the performance fluid responsiveness tests in patients admitted to the intensive care unit. an assessment was performed within the six hours after admission to the intensive care unit. evaluation was based on transthoracic echocardiography, clinical examination of the patients, and data derived from anamnesis. the following fluid responsiveness tests were included into assessment: passive leg raising test, end-expiratory occlusion test, pulse pressure variation, stroke volume variation, velocity time integral variation in left ventricle output track, tidal volume challenge, inferior vena cava diameter variation, and superior vena cava diameter variation. the aim of the study was to assess how many patients have the conditions allowing performance fluid responsiveness tests during admission to the intensive care unit.

Eligibility criteria:
inclusion criteria: 1. adult patients admitted to the intensive care unit exclusion criteria: 1. age under 18 2. the researcher unavailable in the intensive care unit 3. patient assessment cannot be completed within the first six hours after admission to the icu
angiotensin converting enzyme inhibitors in marfan syndrome

Conditions: Marfan Syndrome

Summary: the purpose of this research is to assess the effects of a drug called perindopril on the aorta in people known to have marfan syndrome. the aorta is the major artery of the body that comes out of the heart and supplies blood to the body. we know that in people with marfan syndrome, the aorta is stiff and this stiffness results in its enlargement over many years. this enlargement of the aorta can be very serious. we know from treatment of other heart conditions that drugs of the same type as perindopril reduce stiffness of the arteries. this type of drug has never been tried in people with marfan syndrome.


Eligibility criteria:
inclusion criteria: * age 18-40 * diagnosis of marfan syndrome, on the basis of the ghent criteria exclusion criteria: * age \ 40 * women of child-bearing potential not on adequate contraception * serum creatinine of \>0.11 * a history of intolerance to acei * patients on angiotensin receptor blockers * blood pressure \>140/90mmhg * history of previous aortic surgery

Keywords: marfan syndrome aortic root diameter
comparison of prism iii, pim2 and pelod scoring systems

Conditions: Congenital Heart Disease

Summary: prismiii(pediatric risk of mortality iii), pim2(pediatric index of mortality 2) and pelod(pediatric logistic organ dysfunction) are frequently used for predicting mortality and morbidity in general pediatric icus(intensive care units). however, the effectiveness of these scoring sistems in a specific group patients undergoing congenital heart surgery(chs) is unknown. in this study, the investigators aimed primarily to evaluate the success of these scoring systems in predicting mortality and morbiditiy in this specific group and to compare the scoring systems with eachother, and secondly to evaluate the relationship of these systems with the stat(sts-eacts chs mortality score) category


Eligibility criteria:
inclusion criteria: * patients younger than 18 years of age who had undergone congenital heart surgery exclusion criteria: * emergency operations patients staying in intensive care unit for less than 24 hours

Keywords: prism iii pim2 pelod stat mortality congenital heart disease